Table Summary economic evaluations identified in the literature Gordon et al. (2016) Cerantola et al. (2016) Lotan et al. (2015) Nicholson et al. (2015) de Rooij et al. (2014) Mowatt et al. (2013) Perspective Health care system (Australia) Health care system Not explicitly reported. Healthcare Healthcare Healthcare and out of pocket costs for (Canada) [Provincial perspective perspective perspective (USA) [~societal] patients. public health system] [UK, NHS] [The Netherlands] [UK, NHS] Population Population 1 Population 1 Population 1 Population 1 Population 1 Population 1 Men with suspected PCa who Biopsy naïve men Men with prior Men with suspected Men with elevated Men with prior have not had a prior biopsy. with clinical suspicion negative biopsy PCa with prior PSA (>4ng/mL) who negative biopsy of PCa based on DRE negative or equivocal never had a prostate and PSA > 4-10ng/ml. biopsy biopsy Note: Population 2 are modelled, but are not the baseline cohort. mpMRI with biopsy PCA3 score or phi in MRS/MRI sequences Interventions Strategy 2: mpMRI ± MRIGB MRIGB mpMRI + MRIGB TRUSGB combination with to direct TRUSGB Strategy 3: mpMRI ± (MRIGB or [mpMRI + MRIGB] existing tests TRUSGB or TPUSGB) [comparators as below] Comparator Strategy 1: TRUSGB TRUSGB (12-core) TRUSGB clinical assessment TRUSGB Extended TRUSGB clinical assessment and MRI mpMRI and MRIGB is part of clinical assessment. Type of CEA and CUA CUA Cost analysis CEA and CUA CUA Cost analysis, economic CEA and CUA evaluation Sources of Systematic literature review Literature [unclear if Systematic literature Systematic literature Systematic literature Systematic literature evidence review was review review searches, searches, systematic]; base and expert indirect assumptions were opinion comparison, and made by authors and expert opinion. expert opinion.
Table Summary economic evaluations identified in the literature Gordon et al. (2016) Cerantola et al. (2016) Lotan et al. (2015) Nicholson et al. (2015) de Rooij et al. (2014) Mowatt et al. (2013) Perspective Health care system (Australia) and out of pocket costs for patients. Health care system (Canada) [Provincial public health system] Not explicitly reported. (USA) [~societal] Healthcare perspective [UK, NHS] Healthcare perspective [The Netherlands] Healthcare perspective [UK, NHS] Population Population 1 Men with suspected PCa who have not had a prior biopsy. Population 1 Biopsy naïve men with clinical suspicion of PCa based on DRE and PSA > 4-10ng/ml. Note: Population 2 are modelled, but are not the baseline cohort. Population 1 Men with prior negative biopsy Population 1 Men with suspected PCa with prior negative or equivocal biopsy Population 1 Men with elevated PSA (>4ng/mL) who never had a prostate biopsy Population 1 Men with prior negative biopsy Interventions Strategy 2: mpMRI ± MRIGB Strategy 3: mpMRI ± (MRIGB or TRUSGB or TPUSGB) MRIGB [mpMRI + MRIGB] mpMRI with biopsy TRUSGB PCA3 score or phi in combination with existing tests [comparators as below] mpMRI + MRIGB MRS/MRI sequences to direct TRUSGB Comparator Strategy 1: TRUSGB TRUSGB (12-core) TRUSGB clinical assessment clinical assessment and MRI mpMRI and MRIGB is part of clinical assessment. TRUSGB Extended TRUSGB Type of economic evaluation CEA and CUA CUA Cost analysis CEA and CUA CUA Cost analysis, CEA and CUA Sources of evidence Systematic literature review Literature [unclear if review was systematic]; base assumptions were made by authors and expert opinion. Systematic literature review Systematic literature review Systematic literature searches, and expert opinion Systematic literature searches, indirect comparison, and expert opinion.